Hcw Biologics Inc. (HCWB) Stock Price & Analysis

Hcw Biologics Inc. (HCWB) fell 18.62% to USD 1.18 as of June 9, 2026 at 23:53 UTC, according to Nexqual real-time market data.

HCWB last closed at USD 1.45; the session ranged USD 1.1–1.41 on volume of 872,347 shares. Market capitalization is $8.45M, with a 52-week range of USD 0.25–7.35 (NCM). Source: Nexqual, June 9, 2026 at 23:53 UTC.

Key Statistics (as of June 9, 2026 at 23:53 UTC)

Technical Analysis (HCWB)

Nexqual's technical model rates HCWB "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:53 UTC.

Analyst Ratings (HCWB)

Wall Street analysts rate HCWB "Buy" based on 1 analysts, with a mean price target of USD 5 (range USD 5–5), per Nexqual as of June 9, 2026 at 23:53 UTC.

Earnings (HCWB)

Recent Earnings History

Source: Nexqual, June 9, 2026 at 23:53 UTC.

Financials & Fundamentals (HCWB)

Source: Nexqual, June 9, 2026 at 23:53 UTC.

Financial Health Score (HCWB)

Nexqual rates Hcw Biologics Inc.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:53 UTC.

Ownership (HCWB)

Source: Nexqual, June 9, 2026 at 23:53 UTC.

Leadership (HCWB)

Hcw Biologics Inc. is led by Hing C. Wong (age 71), Founder, CEO, Director & Secretary, per Nexqual as of June 9, 2026 at 23:53 UTC.

Major Backers & Investors (HCWB)

Notable institutional backers of Hcw Biologics Inc. include HRT Financial LP, Virtu Financial LLC, Fidelity, according to Nexqual as of June 9, 2026 at 23:53 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 9, 2026 at 23:53 UTC.

From Hcw Biologics Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• Moreover, the TOBI TM platform is reproducible and suitable for cGMP manufacturing.   T-Cell Receptor β Chain Constant Region ("TRBC") Platform   Our proprietary T-Cell Receptor β Chain Constant Region ("TRBC") Drug Discovery and Development Platform is an immunotherapeutic drug discovery and development technology that the Company used to construct fusion immunotherapeutics that activate immune responses and specifically target cancerous or infected cells.
• Since inception, the Company has recognized $16.2 million of revenues derived from the Wugen License, including upfront license fees in cash and shares of Wugen common stock, payments for vials of materials, and for manufacturing of development supplies for clinical trials.
• Wugen plans to submit a Biologics License Application ("BLA") to the FDA in 2027.
• We also rely on trade secrets relating to our technology platform and on know-how, continuing technological innovation to develop, strengthen, and maintain our proprietary position in the field of inflammaging and the diseases it promotes that may be important for the development of our business.

Partnerships

• As part of a confidential Settlement Agreement with ImmunityBio, Inc. in 2024, the Company assigned certain patents and patent applications to ImmunityBio, Inc., yet the Company retained a world-wide exclusive license in respect of the use of TOBI TM molecules outside of oncology indications.
• Clinical development and commercialization may be accomplished with an internal program or corporate partnership. 7     Our Drug Discovery and Development Platforms   HCW Biologics has combined a deep understanding of disease-related immunology with expertise in advanced protein engineering to develop fusion immunotherapeutics using its two proprietary drug design and discovery platforms.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:53 UTC. This page is informational and not investment advice.